SOLCO HEALTHCARE US, RECEIVES FDA APPROVAL FOR GLYCOPYRROLATE INJECTION, 0.2 mg/mL

SOLCO HEALTHCARE US, RECEIVES FDA APPROVAL FOR GLYCOPYRROLATE INJECTION, 0.2 mg/mL CRANBURY, NJ — Solco Healthcare announces its FDA approval for Glycopyrrolate Injection, 0.2mg/mL, which is an AP-rated equivalent to Robinul® by Hikma. “We are very pleased to have received FDA approval for Glycopyrrolate injection.  This approval represents a new chapter for Solco, as we enter

Press Release – Update on Valsartan API – A Statement from the Company

FOR IMMEDIATE RELEASE – CRANBURY, NEW JERSEY, August 21, 2018. Huahai US Inc., a subsidiary of Zhejiang Huahai Pharmaceutical Co. Ltd is issuing a statement. Recent articles in several print and on-line media have misrepresented information about the discovery of a trace amount of a genotoxic impurity in Valsartan, an active pharmaceutical ingredient (API) made

SOLCO HEALTHCARE US ANNOUNCES THE FDA APPROVAL OF FENOFIBRATE TABLETS, 48mg and 145mg

CRANBURY, NJ — Solco Healthcare is proud to announce its FDA approval for Fenofibrate tablets, 48 mg and 145 mg, which is an AB-rated equivalent to Tricor® by Abbvie. Fenofibrate tablets are indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), Triglycerides and apolipoprotein B (Apo B), and to

SOLCO HEALTHCARE US ANNOUNCES THE LAUNCH OF ENTECAVIR TABLETS

CRANBURY, NJ., April 25, 2018 – Solco Healthcare is proud to announce the launch of Entecavir Tablets, 0.5mg and 1mg, a generic equivalent of Baraclude® Tablets by Bristol-Myers Squibb Company.  Solco is offering Entecavir Tablets, 0.5mg and 1mg, in 30-count bottles to its customers. The product is available for shipment immediately.  Entecavir tablets are used to treat chronic

SOLCO HEALTHCARE US ANNOUNCES THE LAUNCH OF CLONIDINE HCL ER TABLETS

Cranbury, NJ., April 3, 2018.  Solco Healthcare announced today the launch of Clonidine Hydrochloride Extended-Release Tablets, 01.mg, a generic version of Kapvay® Tablets by Concordia Pharmaceuticals Inc.  The product is used for the treatment of attention-deficit/hyperactivity disorder (ADHD). The U.S. Food and Drug Administration (FDA) has granted final approval of its Abbreviated New Drug Application for Clonidine

Solco Healthcare US receives FDA approval for its generic to Abilify® tablets

CRANBURY, NJ – Solco Healthcare U.S. is proud to announce that the U.S. Food and Drug Administration (FDA) approved its generic equivalent of Abilify® Tablets (Aripiprazole tablets), 2, 5, 10, 15, 20 and 30mg.  The product is available for shipment now. Aripiprazole tablets are are indicated for the following: (A) Bipolar I disorder, (B) Irritability, associated

Solco Healthcare US Announces the FDA Approval for its generic to Hyzaar® Tablets

CRANBURY, NJ – Solco Healthcare U.S. is proud to announce that the U.S. Food and Drug Administration (FDA) approved its generic equivalent of Hyzaar® Tablets (Losartan Potassium and Hydrochlorothiazide tablets), 50-12.5mg, 100-12.5mg and 100-25mg.  The product is available now. Losartan Potassium-HCTZ is used to treat high blood pressure (hypertension). It is also used to lower the

Solco Healthcare US Announces the Approval of Generic Cymbalta® Capsules

CRANBURY, NJ – Solco Healthcare U.S. is proud to announce that the U.S. Food and Drug Administration (FDA) approved its generic equivalent of Cymbalta® Capsules (Duloxetine delayed-release capsules), 20mg, 30mg and 60mg.  The product is available now. Duloxetine is used to treat major depressive disorder in adults. Duloxetine is also used to treat general anxiety

Solco Healthcare US Receives FDA Approval for Telmisartan Tablets, 20mg, 40mg and 80mg

CRANBURY, NJ — Solco Healthcare is proud to announce its FDA approval for Telmisartan tablets, 20mg, 40mg and 80mg, which are AB-rated equivalents to Micardis® by Boehringer Ingelheim. “This recent approval continues to support Solco’s ability to provide high quality, cost effective medications to those in need,” said Hai Wang, President of Solco Healthcare. Telmisartan tablets

SOLCO HEALTHCARE INTRODUCES OLMESARTAN MEDOXOMIL and HYDROCHLOROTHIAZIDE Tablets

CRANBURY, NJ — Solco Healthcare today announced the launch of generic version of Daiichi-Sankyo’s Benicar-HCT®, Olmesartan Medoxomil and Hydrochlorothiazide Tablets, 20mg/12.5mg, 40/12.5mg and 40mg/25mg.  Solco received its final approval by the U.S. FDA for its abbreviated New Drug Application (ANDA) via its parent company Prinston Pharmaceutical Inc. Olmesartan Medoxomil and Hydrochlorothiazide Tablets are indicted for